Shares of Biocept Inc. (NASDAQ:BIOC) have been assigned an average broker rating score of 1.67 (Buy) from the three analysts that cover the stock, Zacks Investment Research reports. One equities research analyst has rated the stock with a hold rating and two have assigned a strong buy rating to the company. Biocept’s rating score has declined by 25.6% from 90 days ago as a result of various analysts’ upgrades and downgrades.
Brokerages have set a one year consensus price objective of $4.50 for the company and are anticipating that the company will post ($0.57) EPS for the current quarter, according to Zacks. Zacks has also given Biocept an industry rank of 97 out of 265 based on the ratings given to related companies.
BIOC has been the topic of a number of recent analyst reports. Feltl & Co. lowered shares of Biocept from a “buy” rating to a “hold” rating in a research note on Wednesday, August 3rd. Zacks Investment Research upgraded shares of Biocept from a “hold” rating to a “buy” rating and set a $0.75 price target on the stock in a research note on Wednesday, July 13th. Finally, Rodman & Renshaw set a $2.50 price objective on shares of Biocept and gave the stock a “buy” rating in a research note on Wednesday, August 31st.
Biocept (NASDAQ:BIOC) opened at 1.358 on Friday. The stock’s 50 day moving average is $1.68 and its 200 day moving average is $2.25. Biocept has a 52 week low of $1.26 and a 52 week high of $7.68. The stock’s market cap is $11.40 million.
Biocept (NASDAQ:BIOC) last issued its quarterly earnings results on Tuesday, August 2nd. The company reported ($0.20) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.22) by $0.02. Biocept had a negative net margin of 1,466.69% and a negative return on equity of 764.73%. Analysts predict that Biocept will post $0.40 EPS for the current year.
An institutional investor recently raised its position in Biocept stock. Creative Planning raised its position in Biocept Inc. (NASDAQ:BIOC) by 206.4% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 172,640 shares of the company’s stock after buying an additional 116,300 shares during the period. Creative Planning owned approximately 0.69% of Biocept worth $115,000 as of its most recent SEC filing. Institutional investors and hedge funds own 14.40% of the company’s stock.
Biocept Company Profile
Biocept, Inc is an early commercial-stage molecular oncology diagnostics company. The Company develops and commercializes circulating tumor cell (CTC) and circulating tumor deoxyribonucleic acid (ctDNA), assays utilizing a standard blood sample, or liquid biopsy. The Company’s Target-Selector offering is based on an internally developed, microfluidics-based CTC capture and analysis platform, with enabling features that change how CTC testing can be used by clinicians by providing biomarker detection and monitoring requiring only a standard blood sample.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Biocept Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biocept Inc. and related companies with MarketBeat.com's FREE daily email newsletter.